Mesoblast (NASDAQ:MESO) Shares Up 3.4% – Here’s Why

Mesoblast Limited (NASDAQ:MESO) shares traded up 3.4% on Tuesday . The company traded as high as $11.40 and last traded at $11.40. 454 shares were traded during trading, a decline of 100% from the average session volume of 750,209 shares. The stock had previously closed at $11.03.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Tuesday, September 24th. StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Jefferies Financial Group raised shares of Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Mesoblast Stock Down 0.5 %

The firm has a 50-day moving average price of $9.06 and a 200-day moving average price of $7.72. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MESO. GAMMA Investing LLC grew its stake in shares of Mesoblast by 50.1% in the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after acquiring an additional 1,663 shares during the last quarter. Signaturefd LLC raised its stake in shares of Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after buying an additional 3,099 shares during the period. Perkins Coie Trust Co purchased a new stake in shares of Mesoblast in the second quarter worth $68,000. Pine Valley Investments Ltd Liability Co bought a new position in shares of Mesoblast in the second quarter worth about $80,000. Finally, Rathbones Group PLC purchased a new stake in Mesoblast in the 2nd quarter worth $95,000. Institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.